ReviewCurrent drug targets2026
Targeting the cGAS-STING Pathway in Gastrointestinal Cancers: Modulating Tumor-associated Inflammation for Therapeutic Effect.
Review in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGastrointestinal (GI) tumours are a significant contributor to cancer-related mortality, underscoring the necessity for novel therapeutic approaches. The cGAS-STING pathway, a cytosolic DNA-sensing mechanism, has two effects: it boosts antitumor immunity and also helps the tumour microenvironment inhibit the immune system.
methodsThis review integrates recent preclinical and clinical evidence regarding cGAS-STING signalling in gastrointestinal cancers, emphasising therapeutic strategies including STING agonists, immune checkpoint combinations, nanoparticle delivery, and pathway interactions with DNA damage response, autophagy, and immune surveillance.
resultsEvidence indicates that cGAS-STING activation can improve immune surveillance and therapeutic efficacy; nevertheless, sustained activation may facilitate tumour growth via immune evasion and chronic inflammation. Preclinical evidence indicates the promise of STING agonists and combination treatments, whereas initial clinical trials yield optimistic, although constrained, results. Toxicity, tumour heterogeneity, and resistance mechanisms remain obstacles. DISCUSSION: For therapy to work, it is important to find a balance between the two effects of cGAS- STING. Biomarker-guided medication development, rational combinations, and enhanced delivery technologies are some of the strategies that could lead to better outcomes. Predictive models powered by artificial intelligence also enable grouping patients and tailoring treatments to their needs.
conclusionOne promising avenue for advancing precision oncology in gastrointestinal malignancies is targeting the cGAS-STING pathway. Enhancing efficacy and reshaping cancer treatment could be achieved by overcoming present limits through integrated therapeutic approaches and personalised medicine.
Indexed as
Identifiers
41832730What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.